Ascelia Pharma
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey. The company focuses on developing and commercializing novel drugs for rare cancer conditions, addressing unmet medical needs. Ascelia Pharma's key products include Orviglance, a contrast agent for liver imaging, and Oncoral, an oral chemotherapy drug. The company is listed on NASDAQ Stockholm under the ticker ACE and aims to become a leader in orphan oncology through strategic partnerships and an expanding product pipeline.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueIncludes Orviglance for liver imaging
Includes Oncoral, an oral chemotherapy drug
Research and development of new drugs
Customers
Ascelia Pharma primarily targets healthcare providers and hospitals that require specialized drugs for rare cancer conditions. The company's products are designed for patients with specific medical needs, such as those with liver cancer and kidney impairment. The addressable market for Orviglance is estimated at USD 800 million annually, highlighting the significant demand for alternatives to gadolinium-based contrast agents. Ascelia Pharma's strategy involves partnering with established commercialization partners to reach these healthcare providers effectively.
Purchase specialized cancer drugs for patient treatment
Use contrast agents for imaging procedures
Collaborate for drug distribution and commercialization
Strategy
Ascelia Pharma's strategic priorities include advancing its product pipeline and expanding its market presence through partnerships. The company focuses on launching Orviglance and progressing Oncoral through clinical phases. By partnering with established commercialization entities, Ascelia Pharma aims to minimize investment requirements while maximizing market reach. The company is also committed to strengthening its financial position through strategic financing initiatives.
To establish market presence and generate revenue
To address unmet medical needs and diversify offerings
To leverage established market capabilities
Geography
Ascelia Pharma is headquartered in Malmö, Sweden, with a significant presence in the US through its base in New Jersey. The company's products are marketed globally, with the US accounting for approximately 45% of the market share for Orviglance. Europe and Japan are also key markets, representing 15% and 10% of the market share, respectively. The company's geographic strategy involves leveraging partnerships to expand its reach in these regions.
Risks
Ascelia Pharma faces several risks, including the need for continuous financing to support its development and growth. Market dynamics and financing uncertainties pose challenges to ongoing operations. The company's reliance on partnerships for commercialization introduces dependency risks. Additionally, regulatory hurdles and competition in the pharmaceutical industry are significant risks. The company's financial position is also affected by share-based remuneration and warrant valuations, which can lead to dilution and financial volatility.
- Financing NeedsImpact: CriticalLikelihood: Medium
Continuous funding required for growth and development
- Regulatory HurdlesImpact: HighLikelihood: Medium
Compliance with pharmaceutical regulations
- Partnership DependencyImpact: MediumLikelihood: Low
Reliance on partners for commercialization
Accounting
Judgemental itemsAffects financial income/costs without cash impact
Impact: high
Impacts equity and personnel costs
Impact: medium
Similar listed companies
Publicly listed companies with a comparable business focus.
BioInvent International
BINV · Health Care
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy.
AstraZeneca PLC
AZN · Pharmaceutical Preparations
AstraZeneca PLC is a global biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
ALX Oncology Holdings Inc
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
Ascendis Pharma A/S
ASND · Pharmaceutical Preparations
Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies built on its TransCon technology platform.
Cantargia
CANTA · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Last updated: 24/09/2026